Drug Description in Trials / DrugBank / KEGG DRUG
Search results
Showing 1 to 10 of 23 descriptions
| No. | 薬物名（臨床試験情報から抽出） | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | 指定難病告示番号 | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | All patients in the study will be treated with ocrelizumab | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬1. All patients in the study will be treated with ocrelizumab
| 1件: MS4A1 MS4A1 💬1. All patients in the study will be treated with ocrelizumab
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬1. All patients in the study will be treated with ocrelizumab
| ||||||||||||||||||||||||||||
| 2 | Continued Ocrelizumab | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬2. Continued Ocrelizumab
| 1件: MS4A1 MS4A1 💬2. Continued Ocrelizumab
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬2. Continued Ocrelizumab
| ||||||||||||||||||||||||||||
| 3 | Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolim ... | 12件: Acetate Acetate,Alemtuzumab, Cladribine, Dimethyl fumarate, Fingolimod, Glatiramer, Natalizumab, Ocrelizumab, Ofatumumab, Ponesimod, Rituximab, Teriflunomide 12件: Acetate, Alemtuzumab, Cladribine, Dimethyl fumarate, Fingolimod, Glatiramer, Natalizumab, Ocrelizumab, ... | 10件: Cladribine
Cladribine
,Alemtuzumab , Rituximab , Dimethyl fumarate , Ocrelizumab , Natalizumab , Ofatumumab , Fingolimod , Teriflunomide , Ponesimod 💬 10件: Cladribine , Alemtuzumab , Rituximab , Dimethyl fumarate , Ocrelizumab , Natalizuma ... 3. Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
| 7件: CD52 CD52,DHODH, ITGA4, KEAP1, MS4A1, RRM1, S1PR1 💬 3. Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab | 30件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Biosynthesis of cofactors, Cell adhesion molecules, Chemical carcinogenesis - reactive oxygen species, Dilated cardiomyopathy, Drug metabolism - other enzymes, ECM-receptor interaction, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Glutathione metabolism, Hematopoietic cell lineage, Hepatocellular carcinoma, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, PI3K-Akt signaling pathway, Parkinson disease, Pathways in cancer, Purine metabolism, Pyrimidine metabolism, Regulation of actin cytoskeleton, Sphingolipid signaling pathway, Ubiquitin mediated proteolysis, Yersinia infection 💬 30件: Arrhythmogenic right ventricular cardiomyopathy, Biosynthesis of cofactors, Cell adhesion molec ... | 1件: 13 13 💬3. Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
| ||||||||||||||||||||||||||||
| 4 | OCRELIZUMAB | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬4. OCRELIZUMAB
| 1件: MS4A1 MS4A1 💬4. OCRELIZUMAB
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 3件: 13 13, 46, 49 💬
| ||||||||||||||||||||||||||||
| 5 | Ocrelizumab (CinnaGen, Iran) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬5. Ocrelizumab (CinnaGen, Iran)
| 1件: MS4A1 MS4A1 💬5. Ocrelizumab (CinnaGen, Iran)
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬5. Ocrelizumab (CinnaGen, Iran)
| ||||||||||||||||||||||||||||
| 6 | Ocrelizumab (Roche, Switzerland) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬6. Ocrelizumab (Roche, Switzerland)
| 1件: MS4A1 MS4A1 💬6. Ocrelizumab (Roche, Switzerland)
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬6. Ocrelizumab (Roche, Switzerland)
| ||||||||||||||||||||||||||||
| 7 | Ocrelizumab / rhuMAb 2H7 | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬7. Ocrelizumab / rhuMAb 2H7
| 1件: MS4A1 MS4A1 💬7. Ocrelizumab / rhuMAb 2H7
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬7. Ocrelizumab / rhuMAb 2H7
| ||||||||||||||||||||||||||||
| 8 | Ocrelizumab 300 mg | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬8. Ocrelizumab 300 mg
| 1件: MS4A1 MS4A1 💬8. Ocrelizumab 300 mg
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬8. Ocrelizumab 300 mg
| ||||||||||||||||||||||||||||
| 9 | Ocrelizumab 300mg | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬9. Ocrelizumab 300mg
| 1件: MS4A1 MS4A1 💬9. Ocrelizumab 300mg
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬9. Ocrelizumab 300mg
| ||||||||||||||||||||||||||||
| 10 | Ocrelizumab 300mg /10ml | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬10. Ocrelizumab 300mg /10ml
| 1件: MS4A1 MS4A1 💬10. Ocrelizumab 300mg /10ml
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬10. Ocrelizumab 300mg /10ml
|